Raras
Buscar doenças, sintomas, genes...
Distrofia fúndica de Sorsby
ORPHA:59181CID-10 · H35.5CID-11 · 9B61OMIM 136900DOENÇA RARA

Uma rara distrofia macular (doença que afeta a mácula, a parte central da retina), progressiva e de origem genética (transmitida de forma autossômica dominante). Ela geralmente se manifesta entre os 20 e os 60 anos de idade, sendo caracterizada por atrofia e descolamento da retina. A doença leva à perda da visão central, depois da visão periférica e, por fim, à cegueira.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma rara distrofia macular (doença que afeta a mácula, a parte central da retina), progressiva e de origem genética (transmitida de forma autossômica dominante). Ela geralmente se manifesta entre os 20 e os 60 anos de idade, sendo caracterizada por atrofia e descolamento da retina. A doença leva à perda da visão central, depois da visão periférica e, por fim, à cegueira.

Publicações científicas
95 artigos
Último publicado: 2025

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: H35.5
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
18 sintomas
❤️
Coração
1 sintomas

+ 8 sintomas em outras categorias

Características mais comuns

90%prev.
Lesões amarelas/brancas da mácula
Muito frequente (99-80%)
90%prev.
Perda visual
Muito frequente (99-80%)
90%prev.
Distrofia macular
Muito frequente (99-80%)
90%prev.
Depósitos sub-retinianos
Muito frequente (99-80%)
55%prev.
Espaços hiporrefletivos na OCT macular
Frequente (79-30%)
55%prev.
Imagem anormal de autofluorescência do fundo de olho
Frequente (79-30%)
27sintomas
Muito frequente (4)
Frequente (7)
Ocasional (6)
Sem dados (10)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 27 características clínicas mais associadas, ordenadas por frequência.

Lesões amarelas/brancas da máculaYellow/white lesions of the macula
Muito frequente (99-80%)90%
Perda visualVisual loss
Muito frequente (99-80%)90%
Distrofia macularMacular dystrophy
Muito frequente (99-80%)90%
Depósitos sub-retinianosSubretinal deposits
Muito frequente (99-80%)90%
Espaços hiporrefletivos na OCT macularHyporeflective spaces on macular OCT
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico95PubMed
Últimos 10 anos48publicações
Pico20229 papers
Linha do tempo
2025Hoje · 2026🧪 2014Primeiro ensaio clínico📈 2022Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

TIMP3Metalloproteinase inhibitor 3Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Mediates a variety of processes including matrix regulation and turnover, inflammation, and angiogenesis, through reversible inhibition of zinc protease superfamily enzymes, primarily matrix metalloproteinases (MMPs). Regulates extracellular matrix (ECM) remodeling through inhibition of matrix metalloproteinases (MMP) including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15. Additionally, modulates the processing of amyloid precursor protein (APP) and apolipoprotein E receptor ApoE

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (1)
Platelet degranulation
MECANISMO DE DOENÇA

Sorsby fundus dystrophy

Rare autosomal dominant macular disorder with an age of onset in the fourth decade. It is characterized by loss of central vision from subretinal neovascularization and atrophy of the ocular tissues. Generally, macular disciform degeneration develops in the patients eye within 6 months to 6 years.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
1554.8 TPM
Pulmão
1309.4 TPM
Adipose Visceral Omentum
1067.9 TPM
Artéria tibial
1042.5 TPM
Mama
1019.6 TPM
OUTRAS DOENÇAS (1)
Sorsby fundus dystrophy
HGNC:11822UniProt:P35625

Variantes genéticas (ClinVar)

35 variantes patogênicas registradas no ClinVar.

🧬 TIMP3: NM_000362.5(TIMP3):c.489T>A (p.Cys163Ter) ()
🧬 TIMP3: NM_000362.5(TIMP3):c.544T>C (p.Tyr182His) ()
🧬 TIMP3: NM_000362.5(TIMP3):c.530A>G (p.Tyr177Cys) ()
🧬 TIMP3: NM_000362.5(TIMP3):c.545A>G (p.Tyr182Cys) ()
🧬 TIMP3: NM_000362.5(TIMP3):c.484G>A (p.Glu162Lys) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 114 variantes classificadas pelo ClinVar.

6
102
6
Patogênica (5.3%)
VUS (89.5%)
Benigna (5.3%)
VARIANTES MAIS SIGNIFICATIVAS
SYN3: NM_000362.5(TIMP3):c.602dup (p.Asp202fs) [Conflicting classifications of pathogenicity]
SYN3: NM_000362.5(TIMP3):c.454_455insGTA (p.Tyr152delinsCysAsn) [Uncertain significance]
SYN3: NM_000362.5(TIMP3):c.509C>G (p.Ser170Cys) [Uncertain significance]
SYN3: NM_000362.4(TIMP3):c.-488C>T [Uncertain significance]
SYN3: NM_000362.4(TIMP3):c.-557A>C [Uncertain significance]

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distrofia fúndica de Sorsby

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
48 papers (10 anos)
#1

Sorsby Fundus Dystrophy in an Asian Pedigree: Pathogenic Timp3 P.Y191c Variant Impairs Its Binding with Mmp2/9 and Cellular Localization.

Clinical ophthalmology (Auckland, N.Z.)2025

To characterize the clinical phenotype and elucidate the pathogenic mechanism of the novel TIMP3 p.Y191C variant in a multigenerational Asian pedigree with Sorsby Fundus Dystrophy (SFD). Affected family members underwent comprehensive ophthalmic evaluations. Genetic analysis was performed via whole-exome and Sanger sequencing. An ARPE-19 cell models overexpressing wild-type or mutant TIMP3 were generated. Functional analysis including co-immunoprecipitation (Co-IP), MMP inhibition, and immunofluorescence were performed. A heterozygous TIMP3 p.Y191C variant was identified in seven affected members, co-segregating with bilateral choroidal neovascularization and disciform scarring. The tyrosine-191 residue is highly conserved, and structural/computational analyses predicted that the cysteine substitution introduces a smaller, hydrophobic residue and reduces protein stability. Functionally, the Y191C variant impaired TIMP3 binding to MMP2 and MMP9, reduced its inhibitory activity, and altered MMP2 localization following LPS stimulation. Consistent with this loss of function, the mutant TIMP3 significantly inhibited cell viability and promoted apoptosis in ARPE-19 cells under inflammatory stress. The novel TIMP3 p.Y191C variant causes SFD in an Asian pedigree. Its pathogenicity arises from distinct disruptions in MMP2/9 binding and inhibition, coupled with altered MMP2 localization, thereby providing a mechanistic basis for the disease.

#2

Sorsby Pseudoinflammatory Fundus Dystrophy.

Advances in experimental medicine and biology2025

Sorsby fundus dystrophy (SFD) is a rare autosomal dominant disease with complete penetrance and great variability even within the same mutation.

#3

Differential Diagnosis of Age-Related Macular Degeneration.

Klinische Monatsblatter fur Augenheilkunde2025 Jan

A diagnosis of age-related macular degeneration (AMD) may have a significant impact on a patient's life. Therefore, it is important to consider differential diagnoses, as these can differ considerably from AMD regarding prognosis, inheritance, monitoring and therapy. Differential diagnoses include other macular diseases with drusen, drusen-like changes, monogenic retinal dystrophies, as well as a wide range of other, often rare macular diseases. In this review, clinical examples are presented that illustrate alternative diagnoses to AMD and when these should be considered. These include, amongst others, patients with autosomal dominant drusen, Sorsby fundus dystrophy, pachydrusen, late-onset Stargardt disease, extensive macular atrophy with pseudodrusen (EMAP), pseudoxanthoma elasticum (PXE), North Carolina macular dystrophy, mitochondrial retinopathy, benign yellow dot maculopathy, dome- or ridge-shaped maculopathy, or macular telangiectasia type 2. Die Diagnose der altersabhängigen Makuladegeneration (AMD) kann einen Einschnitt im Leben von Patienten bedeuten. Vor diesem Hintergrund ist es wichtig, Differenzialdiagnosen in Erwägung zu ziehen, da diese sich hinsichtlich Prognose, Vererblichkeit, Kontroll- und Therapiebedarf beträchtlich von der AMD unterscheiden können. Differenzialdiagnosen sind vor allem andere Makulaerkrankungen mit Drusen, drusenähnlichen Veränderungen, weitere monogene Netzhautdystrophien sowie ein breites Spektrum weiterer, oftmals seltener Makulaerkrankungen. In dieser Übersicht werden anhand klinischer Beispiele Befundkonstellationen gezeigt, bei denen eine Differenzialdiagnose der AMD in Erwägung gezogen werden sollte. Unter anderem beinhaltet dies Patienten mit autosomal-dominanten Drusen, Sorsby-Fundusdystrophie, Pachydrusen, spät beginnendem Morbus Stargardt, extensive makuläre Atrophie mit Pseudodrusen (EMAP), Pseudoxanthoma elasticum (PXE), North-Carolina-Makuladystrophie, mitochondriale Retinopathie, Benign Yellow Dot Maculopathy, kuppel- oder leistenförmige Makulopathie und makuläre Teleangiektasien Typ 2.

#4

Metabolic Phenotyping of Healthy and Diseased Human RPE Cells.

Investigative ophthalmology &amp; visual science2024 Sep 03

Metabolic defects in the retinal pigment epithelium (RPE) underlie many retinal degenerative diseases. This study aims to identify the nutrient requirements of healthy and diseased human RPE cells. We profiled nutrient use of various human RPE cells, including differentiated and dedifferentiated fetal RPE (fRPE), induced pluripotent stem cell-derived RPE (iPSC RPE), Sorsby fundus dystrophy (SFD) patient-derived iPSC RPE, CRISPR-corrected isogenic SFD (cSFD) iPSC RPE, and ARPE-19 cell lines using Biolog Phenotype MicroArray Assays. Differentiated fRPE cells and healthy iPSC RPE cells can use 51 and 48 nutrients respectively, including sugars, intermediates from glycolysis and tricarboxylic acid (TCA) cycle, fatty acids, ketone bodies, amino acids, and dipeptides. However, when fRPE cells lose their epithelial phenotype through dedifferentiation, nutrient use becomes restricted to 17 nutrients, primarily sugar and glutamine-related amino acids. SFD RPE cells can use 37 nutrients; however, compared to cSFD RPE and healthy iPSC RPE, they are unable to use lactate, some TCA cycle intermediates, and short-chain fatty acids. Nonetheless, they show increased use of branch-chain amino acids (BCAAs) and BCAA-containing dipeptides. Dedifferentiated ARPE-19 cells grown in traditional culture media cannot use lactate and ketone bodies. In contrast, nicotinamide supplementation promotes differentiation toward an epithelial phenotype, restoring the ability to use these nutrients. Epithelial phenotype confers metabolic flexibility to healthy RPE for using various nutrients. SFD RPE cells have reduced metabolic flexibility, relying on the oxidation of BCAAs. Our findings highlight the potentially important roles of nutrient availability and use in RPE differentiation and diseases.

#5

Generation of an induced pluripotent stem cell line (SJTUGHi003-A) from a patient with Sorsby fundus dystrophy carrying c.484G>A mutation in TIMP3 gene.

Stem cell research2024 Jun

Sorsby fundus dystrophy (SFD) is a rare autosomal dominant disorder with macular dystrophy and severe visual loss. Mutations in TIMP3 gene has been related to SFD with mechanisms unclear. We have successfully reprogrammed the peripheral blood mononuclear cells (PBMCs) from an SFD patient carrying c.484G>A mutation in TIMP3 gene to induced pluripotent stem cells (iPSCs) and characterized their pluripotency and genetic stability. This line may serve as a useful tool to explore the role of TIMP3 in SFD pathogenesis.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC58 artigos no totalmostrando 46

2025

Sorsby Fundus Dystrophy in an Asian Pedigree: Pathogenic Timp3 P.Y191c Variant Impairs Its Binding with Mmp2/9 and Cellular Localization.

Clinical ophthalmology (Auckland, N.Z.)
2025

Sorsby Pseudoinflammatory Fundus Dystrophy.

Advances in experimental medicine and biology
2025

Differential Diagnosis of Age-Related Macular Degeneration.

Klinische Monatsblatter fur Augenheilkunde
2024

Metabolic Phenotyping of Healthy and Diseased Human RPE Cells.

Investigative ophthalmology &amp; visual science
2024

Generation of an induced pluripotent stem cell line (SJTUGHi003-A) from a patient with Sorsby fundus dystrophy carrying c.484G>A mutation in TIMP3 gene.

Stem cell research
2024

Disease-Causing TIMP3 Variants and Deep Phenotyping of Two Czech Families with Sorsby Fundus Dystrophy Associated with Novel p.(Tyr152Cys) Mutation.

International journal of molecular sciences
2024

Review: Mechanisms of TIMP-3 accumulation and pathogenesis in Sorsby fundus dystrophy.

Molecular vision
2024

Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes.

Progress in retinal and eye research
2024

TIMP3 c.319C>T, p.(Arg107Cys): Novel Sequence Variant In Sorsby Fundus Dystrophy.

Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH
2024

Macular neovascularization in inherited retinal diseases: A review.

Survey of ophthalmology
2023

The extracellular microenvironment in immune dysregulation and inflammation in retinal disorders.

Frontiers in immunology
2023

Electrophysiological Evaluation of Macular Dystrophies.

Journal of clinical medicine
2023

Generation of a TIMP3 knockout stem cell line via CRISPR/Cas9 system.

Stem cell research
2022

Deglycosylation Increases the Aggregation and Angiogenic Properties of Mutant Tissue Inhibitor of Metalloproteinase 3 Protein: Implications for Sorsby Fundus Dystrophy.

International journal of molecular sciences
2022

Potential CRISPR Base Editing Therapeutic Options in a Sorsby Fundus Dystrophy Patient.

Genes
2022

Sorsby fundus dystrophy (SFD): A narrative review.

Medicine
2022

Early-Onset TIMP3-Related Retinopathy Associated With Impaired Signal Peptide.

JAMA ophthalmology
2022

Extracellular matrix dysfunction in Sorsby patient-derived retinal pigment epithelium.

Experimental eye research
2022

Choriocapillaris Flow Signal Impairment in Sorsby Fundus Dystrophy.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
2021

Peripheral polypoidal choroidal vasculopathy in Sorsby fundus dystrophy: Report of two cases.

Journal francais d'ophtalmologie
2022

Treatment of Sorsby fundus dystrophy with anti-tumor necrosis factor-alpha medication.

Eye (London, England)
2023

Birt-Hogg-Dubé syndrome associated with chorioretinopathy and nyctalopia: a case report and review of the literature.

Ophthalmic genetics
2022

Visual Dysfunction and Structural Correlates in Sorsby Fundus Dystrophy.

American journal of ophthalmology
2021

Longitudinal phenotypic study of late-onset retinal degeneration due to a founder variant c.562C>A p.(Pro188Thr) in the C1QTNF5 gene.

Ophthalmic genetics
2020

Retinal imaging in inherited retinal diseases.

Annals of eye science
2020

The retinal pigment epithelium in Sorsby Fundus Dystrophy shows increased sensitivity to oxidative stress-induced degeneration.

Redox biology
2020

Quantifying the Separation Between the Retinal Pigment Epithelium and Bruch's Membrane using Optical Coherence Tomography in Patients with Inherited Macular Degeneration.

Translational vision science &amp; technology
2020

A novel TIMP3 mutation associated with a retinitis pigmentosa-like phenotype.

Ophthalmic genetics
2020

In vitro stem cell modelling demonstrates a proof-of-concept for excess functional mutant TIMP3 as the cause of Sorsby fundus dystrophy.

The Journal of pathology
2020

Role of FGF and Hyaluronan in Choroidal Neovascularization in Sorsby Fundus Dystrophy.

Cells
2019

The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain.

Cells
2022

LONG-TERM VISUAL ACUITY PRESERVATION IN SORSBY FUNDUS DYSTROPHY WITH CORTICOSTEROID TREATMENT.

Retinal cases &amp; brief reports
2019

Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism.

Scientific reports
2020

Macular dystrophies: clinical and imaging features, molecular genetics and therapeutic options.

The British journal of ophthalmology
2019

Late-Stage Sorsby Fundus Dystrophy Manifesting Severe Vision Loss in the Absence of Choroidal Neovascularization.

Ophthalmic surgery, lasers &amp; imaging retina
2019

Sorsby fundus dystrophy with polypoidal choroidal vasculopathy: Extending TIMP3 phenotypes.

Clinical &amp; experimental ophthalmology
2019

The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond.

Human mutation
2020

Evaluation of Pro-re-Nata (PRN) and Treat and Extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy.

European journal of ophthalmology
2019

Sorsby fundus dystrophy: Insights from the past and looking to the future.

Journal of neuroscience research
2021

PERIPHERAL RETINAL DRUSEN-LIKE DEPOSITS IN GUCY2C CONGENITAL SECRETORY DIARRHEA SYNDROME.

Retinal cases &amp; brief reports
2017

Sorsby fundus dystrophy - A review of pathology and disease mechanisms.

Experimental eye research
2017

Bilateral choroidal neovascular membrane in a young patient with Sorsby fundus dystrophy: the value of prompt treatment.

BMJ case reports
2016

A new autosomal dominant eye and lung syndrome linked to mutations in TIMP3 gene.

Scientific reports
2016

OCT angiography in the management of choroidal neovascular membrane secondary to Sorsby fundus dystrophy.

BMJ case reports
2015

Reticular Pseudodrusen in Sorsby Fundus Dystrophy.

Ophthalmology
2015

Sorsby Fundus Dystrophy: Novel Mutations, Novel Phenotypic Characteristics, and Treatment Outcomes.

Investigative ophthalmology &amp; visual science
Ver todos os 58 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distrofia fúndica de Sorsby.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distrofia fúndica de Sorsby

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Sorsby Fundus Dystrophy in an Asian Pedigree: Pathogenic Timp3 P.Y191c Variant Impairs Its Binding with Mmp2/9 and Cellular Localization.
    Clinical ophthalmology (Auckland, N.Z.)· 2025· PMID 41394255mais citado
  2. Sorsby Pseudoinflammatory Fundus Dystrophy.
    Advances in experimental medicine and biology· 2025· PMID 40736822mais citado
  3. Differential Diagnosis of Age-Related Macular Degeneration.
    Klinische Monatsblatter fur Augenheilkunde· 2025· PMID 39820891mais citado
  4. Metabolic Phenotyping of Healthy and Diseased Human RPE Cells.
    Investigative ophthalmology &amp; visual science· 2024· PMID 39230994mais citado
  5. Generation of an induced pluripotent stem cell line (SJTUGHi003-A) from a patient with Sorsby fundus dystrophy carrying c.484G&gt;A mutation in TIMP3 gene.
    Stem cell research· 2024· PMID 38640637mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:59181(Orphanet)
  2. OMIM OMIM:136900(OMIM)
  3. MONDO:0007640(MONDO)
  4. GARD:16480(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q30314095(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Distrofia fúndica de Sorsby

ORPHA:59181 · MONDO:0007640
Prevalência
Unknown
Herança
Autosomal dominant
CID-10
H35.5 · Distrofias hereditárias da retina
CID-11
Início
Adult
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0339515
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades